IMAGEOMICS
Optimizing Benefit/Risk Ratio in Breast Cancer Diagnosis and Radiotherapy: Identifying Molecular, Cellular and Imaging Signatures of Breast Cancer Heterogeneity to Improve Personalized Therapeutic Strategies for Synergistic Treatment Combinations
Informazioni Generali
- Coordinatore:
- NNGYK - NATIONAL CENTRE FOR PUBLIC HEALTH AND PHARMACY (Ungheria)
- Responsabile:
- ANTONELLI FRANCESCA - SSPT-BIOTEC-RED (CASACCIA)
- Ruolo ENEA:
- PARTNER
Programmi Europei
- Programma:
- HORIZON EUROPE (2021-2027) -> Euratom radioprotezione (Programme Cofund Actions)
Descrizione e Attività
Descrizione Generale
A major objective of PIANOFORTE is to innovate in ionising radiation based medical diagnostic and
therapeutic applications combating cancer to improve patient health and safety. Combating cancer is in
the focus of other EUinitiatives as well, such as the Samira action plan, Europe’s Beating Cancer Plan
and Horizon Europe Mission on Cancer. IMAGEOMICS adheres to these initiatives by proposing new
imaging modality to improve cancer diagnosis and solutions to increase the benefit of cancer patients
from radiotherapy.
The main aims of IMAGEOMICS are to improve benefit/risk ratio of breast cancer (BC) patients by
identifying patients with a predicted favourable response to combined radiotherapy (RT) and
immunotherapy and to develop new imaging modality with increased diagnostic potential and reduced
ionizing radiation exposure. These aims will be realized through the following specific objectives: a)
investigate how RT influences immunogenic heterogeneity of BC cells of different molecular subtypes
using in vitro and in vivo approaches; b) test the applicability of nanoparticles for X ray fluorescence
computed tomography (XFCT) to be used for the detection of BC heterogeneity; c) to identify local and
systemic signatures that predict patient benefit from combined RT and immunotherapy and test their
clinical applicability; d) to integrate data retrieved from experimental models and human studies with
epidemiological data to build up a protocol for optimal patient stratification. High-throughput techniques
such as immunopeptidome analysis and spatial multiomics analysis coupled with single cell imaging will
be used. The innovative aspects of the project rely on providing an integrative analysis based on in vitro
(3D bioprints, organ-on-a-chip systems), in vivo and human studies on markers reflecting interactions
between BC RT and immunotherapy as well as investigating the applicability of molecularly targeted
nanoparticles to be used in XFCT, opening the possibility for further developments in their theranostic
application. The successful completion of IMAGEOMICS tasks is guaranteed by its multidisciplinary
team, involving radiation physicists, radiation oncologists, radiation and molecular biologists, as well as
epidemiologists, all strongly committed to advance radiation protection research for the benefit of the
public and patients.
Attività svolta da ENEA
L’ENEA rivestirà il ruolo di Partner. Non sono previste attività tecnico-scientifiche: il progetto prevede che l'ENEA dovrà garantire esclusivamente la gestione dei rapporti con la UE e il trasferimento del flusso economico verso l’Affiliated Entity (AE) “Laboratorio di Biofisica delle Radiazioni e Radiobiologia dell’Università di Pavia”
Dati Finanziari (in euro)
Costo Eleggibile
Contributo
Durata del Progetto
Partner (7)
Keyword CORDIS (4)
Altre Keyword (4)
2 Rif. Progetto PIANOFORTE Id 101061037